Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2011-06-02 Board/Management Inform…
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, which includes multiple items such as the employment agreement of a new CEO, election of new directors, amendments to articles of incorporation, and detailed voting results from the Annual Meeting of Stockholders. The key content includes the election of directors, approval of amendments, and voting results, which are typical of announcements related to board and management changes. The document is not an annual report, earnings release, or financial statement, but rather a regulatory filing reporting changes in management and board composition, as well as corporate governance actions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2011-06-02 English
FORM 4
Director's Dealing
2011-05-31 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 26, 2011, reporting on the company's Annual Stockholders Meeting. It includes a corporate update and a slide presentation attached as Exhibit 99.1. The text specifically mentions the presentation was given at the Annual Stockholders Meeting and is attached as slides. The document length is 3163 characters, which is relatively short and mainly serves as a disclosure of the presentation material rather than the full report itself. According to the 'Menu vs Meal' rule, this is an announcement of a report (the presentation slides) rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2011-05-26 English
FORM 10-Q
Interim / Quarterly Report Q1 2011
2011-05-13 English
Regulatory Filings 2011
Regulatory Filings
2011-05-11 English
Regulatory Filings 2011
Regulatory Filings
2011-05-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.